Maximizing Trial Value in Resource-Constrained Biotechs

In this episode of the Driving the Business of Science podcast, host Keith Parent, CEO of Court Square Group, speaks with Nathalie Riebel, CEO and founder of Oncospire Consultants, a consultancy specializing in small biotechs. Nathalie points to the $80 billion pharma outsourcing market and the performance and quality challenges that accompany it. The data consistently shows that this massive transfer of work is plagued by delays, quality failures, sponsor dissatisfaction, and governance gaps that remain stubbornly unresolved. The conversation emphasizes the need for small biotechs to effectively manage vendors and drive results. Oncospire’s "Clinical Momentum Method" helps companies to streamline processes and reduce oversight time. Oncospire provides packages for CRO selection, gap assessment (Critical Path Visibility Assessment), and operational improvements, aiming to save small biotechs time and money in the management of their full-service CROs and vendors.Driving the Business of Science is the podcast for clinical operations, IT, and business managers in the pharma, biotech, and medical device world.Bringing new products to market takes more than just great science. From R&D and clinical to regulatory and approval life science leaders require fit-for-purpose technology, processes, and partners at step.In the Driving the Business of Science podcast leaders from across the life science industry share real-world experiences and practical insights that will impact your business.Join host Keith Parent, serial life science CEO, as business leaders share experiences and insights on emerging challenges in the life science market.